Diagnosis and clinical management of patients with Hepatitis Delta
AISF and SIMIT operational indications
The arrival of new treatments for patients suffering from chronic hepatitis Delta virus (HDV) capable of interfering with the life cycle of this virus, with consequent improvement of liver necrosis indices and the course of the disease itself, has pushed AISF (Italian Association for the Study of the Liver) and SIMIT (Italian Society of Infectious and Tropical Diseases) to generate operational indications with the aim of providing practical recommendations on the diagnosis and treatment of patients with HDV.
The document will be updated regularly to reflect the expected progress in the coming months/years for this disease
HDV infection causes the most severe form of chronic viral hepatitis, with rates of progression to cirrhosis and hepatocarcinoma (HCC) significantly higher than HBV monin- infection.The HDV virus requires the presence of HBV to give rise to the complete virion capable of infecting hepatocytes and causing liver disease.
The prevalence of HDV in Italy is estimated to be 3.2% in the HBsAg positive population and 9.3% in chronic HBsAg positive hepatopathic patients in clinical follow-up (about 10,000 patients); higher percentages are recorded in patients from Eastern Europe, the Indian subcontinent or other areas where the disease is endemic
— Reproduction reserved and for personal use
— Download the complete document in PDF format from the link at the bottom of the page
Access to the site is limited and reserved for healthcare professionals
You have reached the maximum of visits
Source — https://www.univadis.it/viewarticle/diagnosi-e-gestione-clinica-del-paziente-affetto-da-epatite-delta